Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Depreciation & Amortization (CF) (2022 - 2025)

Entrada Therapeutics (TRDA) has 4 years of Depreciation & Amortization (CF) data on record, last reported at $900000.0 in Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) fell 10.0% year-over-year to $900000.0; the TTM value through Dec 2025 reached $4.1 million, up 10.81%, while the annual FY2025 figure was $4.1 million, 7.89% up from the prior year.
  • Depreciation & Amortization (CF) reached $900000.0 in Q4 2025 per TRDA's latest filing, down from $1.2 million in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $1.2 million in Q3 2025 and bottomed at $400000.0 in Q1 2022.
  • Average Depreciation & Amortization (CF) over 4 years is $779062.5, with a median of $847500.0 recorded in 2023.
  • Peak YoY movement for Depreciation & Amortization (CF): soared 72.64% in 2024, then dropped 10.0% in 2025.
  • A 4-year view of Depreciation & Amortization (CF) shows it stood at $526000.0 in 2022, then skyrocketed by 33.08% to $700000.0 in 2023, then surged by 42.86% to $1.0 million in 2024, then fell by 10.0% to $900000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Depreciation & Amortization (CF) were $900000.0 in Q4 2025, $1.2 million in Q3 2025, and $1.1 million in Q2 2025.